Pharmaceuticals, Biotechnology and Life Sciences
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform…
ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash…
Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial…
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…
– Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP –…
BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced…
Veteran life sciences executive and dealmaker to drive strategic partnerships, capital formation, and corporate growth initiativesBOSTON, Nov. 11, 2025 (GLOBE…
IRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced…
COSCIENS voluntarily delists from Nasdaq, while retaining the Company’s listing on the TSX COSCIENS restructuring results in significantly lower cash…
PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a…